Development stage company focusing in drug delivery systems technologies within the industry CTT Pharmaceutical Holding Inc. (OTCPINK: CTTH) announced having receives an affirmation from that Canadian law firm Gowlings WLC that CTT’s Canadian patent CA2624110 covering orally administered wafers applies to all forms of psychedelic applications.
According to the legal counsel of Gowlings WLC, the Canadian patent is quite broad covering across a wide area meaning that it’s not limited to any pharmaceutical agent including psychedelics compound or cannabinoids.
“The Canadian patent is quite broad. It is not limited with respect to including any particular pharmaceutical agent and thus… this patent would cover a film including any additional ingredient, including any drug such as a psychedelic drug, cannabinoids, etc,” said Gowlings.
This patent was issued in Canada and it cuts across a wide range protection while covering additional applications in administration of psychedelics not limited to MDMA, DMT, LSD, Ketamine and psilocybin.